First experience in treating advanced urothelial cancer with enfortumab vedotin. Single-centre retrospective study of patients qualified for a rescue access procedure

First experience in treating advanced urothelial cancer with enfortumab vedotin. Single-centre retrospective study of patients qualified for a rescue access procedure

Saved in:

Bibliographic Details
Main Authors:	Bożena Sikora-Kupis, Piotr Domański, Weronika Fortuniak, Barbara Kruczyk, Szymon Staneta, Mateusz Piętak, Anna Mydlak, Tomasz Demkow, Paulina Dumnicka, Jakub Kucharz
Format:	Article
Language:	English
Published:	Termedia Publishing House 2024-01-01
Series:	Contemporary Oncology
Subjects:	advanced urothelial cancer enfortumab vedotin (ev) antibody-drug conjugates (adc) toxicity
Online Access:	https://www.termedia.pl/First-experience-in-treating-advanced-urothelial-cancer-with-enfortumab-vedotin-Single-centre-retrospective-study-of-patients-qualified-for-a-rescue-access-procedure,3,52310,1,1.html
Tags:	Add Tag No Tags, Be the first to tag this record!

Similar Items

Efficacy of modified enfortumab vedotin ineligible criteria (mEVITA) in advanced urothelial carcinoma
by: Takafumi Fukushima, et al.
Published: (2025-07-01)

Dramatic Response to Enfortumab Vedotin in Soft-tissue Metastases from Urothelial Carcinoma: A Case Report
by: Ming-Hsuan Wu, et al.
Published: (2024-12-01)

Enfortumab Vedotin–Induced Toxic Epidermal Necrolysis in Metastatic Urothelial Carcinoma Complicated by Severe Gastrointestinal Bleeding
by: Aika Matsuyama, et al.
Published: (2025-07-01)

Strategies to overcome resistance to enfortumab vedotin and pembrolizumab for patients with urothelial carcinoma: harnessing present knowledge for future advances
by: Albert Jang, et al.
Published: (2025-04-01)

Mechanistic Insights and Future Directions for Enfortumab Vedotin in Urothelial Carcinoma: Highlights from the 10th Annual Leo & Anne Albert Institute for Bladder Cancer Care and Research Symposium
by: Catherine C. Fahey, et al.
Published: (2025-05-01)

Lung Toxicity Occurring During Enfortumab Vedotin Treatment: From a Priming Case Report to a Retrospective Analysis
by: Grégoire Desimpel, et al.
Published: (2024-11-01)

Use of dupilumab to manage a grade 3 cutaneous adverse effect from enfortumab vedotin/pembrolizumab treatment in a patient with metastatic urothelial carcinoma
by: Maura C. Gillis, BA, et al.
Published: (2025-02-01)

Progress of antibody–drug conjugates in the treatment of locally advanced or metastatic urothelial carcinoma: opportunities and challenges
by: Fanhao Zeng, et al.
Published: (2025-05-01)

Real‐Life Impact of Enfortumab Vedotin or Chemotherapy in the Sequential Treatment of Advanced Urothelial Carcinoma: The ARON‐2 Retrospective Experience
by: Mimma Rizzo, et al.
Published: (2025-02-01)

Severe cutaneous toxicity in a 67-year-old patient with metastatic urothelial carcinoma undergoing therapy with enfortumab vedotin and pembrolizumab
by: Benjamin Müller, et al.
Published: (2024-11-01)

Novel combination therapy for platinum-eligible patients with locally advanced or metastatic urothelial carcinoma: a systematic review and network meta-analysis
by: Takafumi Yanagisawa, et al.
Published: (2025-02-01)

Effectiveness and safety of PD-1/L1 inhibitors as first-line therapy for patients with advanced or metastatic urothelial carcinoma who are ineligible for platinum-based chemotherapy: a meta-analysis
by: Weiming Liang, et al.
Published: (2025-02-01)

Enfortumab vedotin induced interstitial lung disease: A first case report with pathological evidence from transbronchial lung cryobiopsy
by: Shota Kaburaki, et al.
Published: (2025-01-01)

Enfortumab vedotin therapy complicated by bullous dermatitis: A case report
by: Roxana A. Hojjatie, BS, et al.
Published: (2025-07-01)

Targeted therapeutic strategies for Nectin-4 in breast cancer: Recent advances and future prospects
by: Yufei Wang, et al.
Published: (2025-02-01)

Recognition and management of adverse cutaneous reactions in patients on enfortumab vedotin and pembrolizumab in the inpatient setting
by: Emma L. Myers, BA, et al.
Published: (2025-04-01)

Efficacy and safety of first-line immunotherapy-containing regimens compared with chemotherapy for advanced or metastatic urothelial carcinoma: a network meta-analysis of randomized controlled trials
by: Weiming Liang, et al.
Published: (2024-12-01)

Interstitial lung disease induced by Toripalimab combined with disitamab Vedotin in upper tract urothelial carcinoma: a case report and literature review
by: Peng Ding, et al.
Published: (2025-07-01)

Anti-Cancer Drug-Induced Lyell’s Syndrome: A Series of Two Patients
by: Julie Coussirou, et al.
Published: (2024-11-01)

Intravesical Disitamab Vedotin (RC48) for HER2‐Expressing High‐Risk Non‐Muscle‐Invasive Bladder Cancer: A Single‐Arm, Dose–Escalation Phase I Trial Study
by: Xu Chen, et al.
Published: (2025-07-01)

Brentuximab Vedotin: New Possibilities for Treatment of Relapses and Refractory Hodgkin’s Lymphomas
by: EA Demina
Published: (2015-10-01)

Retreatment with brentuximab vedotin for discordant peripheral T-cell lymphomas
by: Gen Hasegawa, et al.
Published: (2025-01-01)

The Use of Brentuximab Vedotin in Relapsed/Refractory Hodgkin’s Lymphoma in the Kransnodar Region
by: OD Serdyuk, et al.
Published: (2018-01-01)

Salvage Surgery Following Remarkable Tumor Shrinkage With Enfortumab Vedotin in Advanced Urothelial Carcinoma
by: Keita Minami, et al.
Published: (2025-05-01)

Response of Patients with Taxane-Refractory Advanced Urothelial Cancer to Enfortumab Vedotin, a Microtubule-Disrupting Agent
by: Makito Miyake, et al.
Published: (2023-01-01)

Pharmacoeconomic analysis of therapy with brentuximab vedotin, nivolumab and pembrolizumab in patients with relapsed Hodgkin’s lymphoma
by: N. A. Avxentyev, et al.
Published: (2020-12-01)

Signal mining and risk analysis of tisotumab vedotin adverse events based on the FAERS database
by: JuanJuan Li, et al.
Published: (2025-08-01)

Artificial Intelligence and Novel Technologies for the Diagnosis of Upper Tract Urothelial Carcinoma
by: Nikolaos Kostakopoulos, et al.
Published: (2025-05-01)

Hodgkin Lymphoma Treatment With Brentuximab Vedotin in a Patient With HIV, Liver Failure, and Anemia Without Transfusion
by: Ellen Marin, et al.
Published: (2025-02-01)

Stevens–Johnson syndrome-like cutaneous toxicity with enfortumab vedotin in treating metastatic urothelial carcinoma: A case report
by: Yun-Chang Li, et al.
Published: (2024-11-01)

Enfortumab vedotin plus pembrolizumab for previously untreated locally advanced or metastatic urothelial carcinoma: a cost-effectiveness analysis
by: Youwen Zhu, et al.
Published: (2025-01-01)

Genetic Alterations in Chromatin Regulatory Genes in Upper Tract Urothelial Carcinoma and Urothelial Bladder Cancer
by: Shuo Wang, et al.
Published: (2024-11-01)

The efficacy and safety of Tisotumab vedotin in the treatment of recurrent/metastatic cervical cancer: a systematic review and meta-analysis of single-arm studies
by: Siyuan Zeng, et al.
Published: (2025-05-01)

Brentuximab vedotin (Adcetris®) in therapy of system anaplastic large cell lymphoma. Case report
by: A. A. Semenova, et al.
Published: (2019-01-01)

Salvage chemotherapy in the intensive care unit: a case report of successful treatment of a critically ill patient with metastatic testicular germ cell tumor
by: Karol Grela, et al.
Published: (2025-06-01)

Matching-Adjusted Indirect Comparison of the Efficacy and Safety of Erdafitinib vs Enfortumab Vedotin in Patients with Locally Advanced Metastatic Urothelial Carcinoma
by: Suzy Van Sanden, et al.
Published: (2024-08-01)

SUCCESSFUL USE OF BRENTUXIMAB VEDOTIN IN THE TREATMENT OF PROGRESSIVE PERIPHERAL UNSPECIFIED T-CELL LYMPHOMA IN AN ELDERLY FEMALE PATIENT
by: L. G. Gorenkova, et al.
Published: (2017-06-01)

PRIMARY PALATAL ALK-NEGATIVE ANAPLASTIC LARGE CELL LYMPHOMA: RARITY TREATED SUCCESSFULLY WITH BRENTUXIMAB VEDOTIN
by: Müjgan Çözeli, et al.
Published: (2024-12-01)

Brentuximab vedotin in children and adolescents with Hodgkin’s lymphoma and anaplastic large cell lymphoma – literature review and own experience
by: N. V. Myakova, et al.
Published: (2016-03-01)

Therapeutic strategies for asymptomatic upper urinary tract urothelial carcinoma
by: Deng Lin, et al.
Published: (2022-12-01)